Investing in Advaxis, Inc. (ADXS)  ➔  Intrinsic value

Prev. close$0.47 
ModelValueUpside
Chepakovich$0.21-55%
Graham-Dodd$0.00-100%
Graham$5.15+990%
Previous Close$0.47  
Valuation MethodValuePotential 
Chepakovich Model$0.21-55%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$5.15+990%recalculate

Latest news

Company description

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) which is phase II clinical trial for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product developed using whole-exome sequencing of a patient's tumor to identify neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.